Project Grant R21NS150643
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $446K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded Cincinnati Children's Hospital Medical Center $1.614 million on September 11, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct basic research on epileptogenesis mechanisms in mtoropathies and develop AAV-mediated gene therapy approaches for intractable epilepsy caused by mTOR pathway mutations. The research leverages newly developed mouse models of...
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded $445,500 to Cincinnati Children's Hospital Medical Center on July 25, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct preclinical research on microRNA-mediated regulation of IL-17A-associated neurodevelopmental defects induced by maternal immune activation. The...
- The National Institute of Neurological Disorders and Stroke awarded Mayo Clinic $219,510 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop noninvasive cell-free DNA biomarkers for early detection and treatment monitoring of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1. The research will integrate cell-free DNA epigenomic features—including methylation patterns and...
- The National Institute of Neurological Disorders and Stroke awarded $616,577 to the Research Institute At Nationwide Children's Hospital on August 14, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to elucidate cellular and molecular disease mechanisms in Charcot-Marie-Tooth type 1B disease and develop gene therapy approaches. The recipient will pursue two aims. In Aim 1, the institute will determine how myelin protein zero...
- The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $858,033 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, titled "TARGETING SCHWANN CELL-IMMUNE INTERACTIONS IN NEUROFIBROMATOSIS TYPE 1", will fund research focused on improving treatment approaches for neurofibromatosis type 1, a genetic disorder that causes tumor growth in the nervous system. The grant award period runs from...
- The National Institute of Neurological Disorders and Stroke awarded Cincinnati Children's Hospital Medical Center $886,875 on April 13, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate phenotype-genotype relationships in tuberous sclerosis. The research will test the hypothesis that distinct human TSC2 mutations contribute to variability in disease severity among tuberous sclerosis patients, and will evaluate...
- The National Institute of Neurological Disorders and Stroke awarded Seattle Children's Hospital $516,175 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the role of MN1 in central nervous system developmental malformations. The research compares MN1 null and C-terminal truncation mutant mice to characterize cerebellar and cerebral cortex phenotypes associated with MN1 C-terminal truncation syndrome,...
- The National Institute of Neurological Disorders and Stroke awarded Miami University $539,920 on September 5, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate how TSC1 loss disrupts Purkinje neuron axon initial segment organization and cerebellar function in autism spectrum disorder. The research examines the cellular mechanisms by which TSC1 deletion in Purkinje neurons alters axon initial segment function and...
- The National Institute of Neurological Disorders and Stroke awarded the University of Virginia $490,593 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the role of growth differentiation factor 11 (GDF11) in neurodevelopmental disorders. The research examines GDF11 as a molecular hub involved in abnormal brain function across multiple genetically distinct neurodevelopmental disorders. The first...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services, awarded Boston Children's Hospital $577,573 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds functional validation of candidate genes implicated in refractory focal epilepsy, with emphasis on mosaic variants in mTOR pathway genes and non-mTOR genes such as SLC35A2. Boston Children's...